Lv11
100 积分 2024-04-19 加入
A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors’ failure: a review of current and investigational treatment for HR+/Her2- breast cancer
1小时前
已完结
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes
1小时前
已完结
478P Germline BRCA1/2 pathogenetic variants (gBRCA1/2 PV) affect outcome of hormone (HR)-positive HER2-negative metastatic breast cancer (MBC) patients (pts) treated with cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus endocrine therapy (ET): The BREAK study
2小时前
已完结
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
2小时前
已完结
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation
9天前
已完结
Systematic review of atypical hemolytic uremic syndrome biomarkers
10天前
已完结
Soluble Membrane Attack Complex: Biochemistry and Immunobiology
17天前
已完结
[Consensus on diagnosis and treatment of complement-mediated kidney diseases]
24天前
已完结
Olezarsen and Plozasiran in Dyslipidemia Management: A Narrative Review of Clinical Trials
1个月前
已完结
The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity
2个月前
已完结
皖公网安备34019202002308
